This segment focuses on the research, development, and clinical evaluation of targeted anticancer therapies. The primary focus is on utilizing tumor-associated biomarkers to identify and develop novel treatments for various cancers. Research and development activities include drug discovery, preclinical studies, and clinical trials. The company is currently conducting Phase I/II clinical trials for Cordycepin (OVI-123) for refractory TdT positive leukemias. The segment also includes pre-clinical development of L-Nucleoside Conjugates (OVI-117) for colon cancer. The company aims to improve patient outcomes by providing innovative and effective cancer treatments. Market positioning is based on the development of targeted therapies with the potential for improved efficacy and reduced side effects. Future opportunities include expanding the pipeline with additional product candidates and exploring partnerships to accelerate development and commercialization. Regulatory and clinical aspects involve navigating the FDA approval process and adhering to clinical trial regulations. The company is actively seeking collaborations to advance its research and development efforts.